AEterna Zentaris Inc. (NASDAQ:AEZS) Price Target Raised to $4.00
AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) had its target price upped by Maxim Group from $2.00 to $4.00 in a research note released on Wednesday morning, MarketBeat Ratings reports. Maxim Group currently has a buy rating on the biopharmaceutical company’s stock.
Several other equities research analysts have also commented on AEZS. Zacks Investment Research upgraded shares of AEterna Zentaris from a sell rating to a hold rating in a research report on Tuesday, July 11th. HC Wainwright set a $3.00 price objective on shares of AEterna Zentaris and gave the stock a buy rating in a research report on Wednesday, July 5th.
AEterna Zentaris (AEZS) traded up 2.50% during trading on Wednesday, hitting $2.87. 17,690,993 shares of the stock traded hands. The stock’s market cap is $41.14 million. The company’s 50 day moving average price is $1.10 and its 200-day moving average price is $2.16. AEterna Zentaris has a 52-week low of $0.78 and a 52-week high of $5.59.
AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last released its quarterly earnings data on Monday, May 8th. The biopharmaceutical company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.02. AEterna Zentaris had a negative net margin of 2,732.69% and a negative return on equity of 425.52%. The business had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.85 million. During the same period in the previous year, the firm earned ($0.37) EPS. The business’s revenue for the quarter was up 8.3% compared to the same quarter last year. Equities research analysts forecast that AEterna Zentaris will post ($1.36) earnings per share for the current fiscal year.
AEterna Zentaris Company Profile
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.
Receive News & Ratings for AEterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.